Complete response after pertuzumab plus trastuzumab plus docetaxel in metastatic Her2-positive breast cancer patients: review of four cases

被引：1

作者：

Lai-Tiong, F. ^{[1
]}

机构：

[1] Gard Canc Inst, Oncol Unit, Rue Prof Henri Pujol, F-30900 Nimes, France

来源：

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY | 2018年 / 39卷 / 05期

关键词：

Pertuzumab; Her2-positive breast cancer; Metastases; Complete response;

D O I：

10.12892/ejgo4026.2018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Her2-positive breast cancers represent about 20 percent of breast cancer patients. Her2-positive breast cancers have more aggressive and poorer prognosis. However, with the emergence of new therapies, outcomes have changed with improvement in survival. Pertuzumab is a new drug, a monoclonal antibody against Her2, available for use in the treatment of Her2-positive breast cancer.

引用

页码：845 / 846

页数：2

共 50 条

[31] Patients with operable HER2-positive breast cancer appear to benefit from the addition of pertuzumab to trastuzumab plus chemotherapy
Printz, Carrie
CANCER, 2020, 126 (09) : 1827 - 1827
[32] Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer
Liu, Yan-cui
Ma, Ying
An, Ning
Sun, Ping
Wang, Ying
Sun, Cheng
MEDICINE, 2019, 98 (38)
[33] Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy
Li, Jiayi
Zhang, Shuang
Ye, Chen
Liu, Qian
Cheng, Yuanjia
Ye, Jingming
Liu, Yinhua
Duan, Xuening
Xin, Ling
Zhang, Hong
Xu, Ling
JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (02):
[34] Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study
Zhang, Ruyan
Liu, Xiaoran
Song, Guohong
Zhang, Yan
Li, Huiping
CANCER RESEARCH AND TREATMENT, 2024, 56 (03): : 795 - 801
[35] Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Swain, Sandra M.
Ewer, Michael S.
Cortes, Javier
Amadori, Dino
Miles, David
Knott, Adam
Clark, Emma
Benyunes, Mark C.
Ross, Graham
Baselga, Jose
ONCOLOGIST, 2013, 18 (03): : 257 - 264
[36] Pertuzumab plus trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway.
Javle, Milind M.
Hainsworth, John D.
Swanton, Charles
Burris, Howard A.
Kurzrock, Razelle
Sweeney, Christopher
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[37] Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K] pertuzumab (P) vs docetaxel plus carboplatin plus trastuzumab plus P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE)
Hurvitz, Sara A.
Martin, Miguel
Symmans, William Fraser
Jung, Kyung Hae
Huang, Chiun-Sheng
Thompson, Alastair Mark
Harbeck, Nadia
Valero, Vicente
Stroyakovskiy, Daniil
Wildiers, Hans
Afenjar, Karen
Fresco, Rodrigo
Helms, Hans -Joachim
Xu, Jin
Lin, Yvonne Gail
Sparano, Joseph A.
Slamon, Dennis J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[38] Predictions of pathological response after preoperative chemotherapy plus trastuzumab in HER2-positive breast cancer
Takada, Masahiro
Sugimoto, Masahiro
Masuda, Norikazu
Iwata, Hiroji
Kuroi, Katsumasa
Yamashiro, Hiroyasu
Ohno, Shinji
Ishiguro, Hiroshi
Inamoto, Takashi
Toi, Masakazu
ANNALS OF ONCOLOGY, 2015, 26 : 78 - 78
[39] A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer
Tolaney, S. M.
Najita, J.
Chen, W.
Savoie, J.
Fornier, M.
Krop, I. E.
Winer, E. P.
Bunnell, C.
CANCER RESEARCH, 2009, 69 (02) : 243S - 243S
[40] Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer
Baez-Vallecillo, L.
Raghavendra, A. Singareeka
Hess, K.
Moulder, S. L.
Tripathy, D.
Valero, V.
Murthy, R. K.
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →